Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
FRAT2
Introduction
GSK-3-binding protein FRAT2 is a protein that in humans is encoded by the FRAT2 gene.[1][2][3]
The protein encoded by this intronless gene belongs to the GSK-3-binding protein family. Studies show that this protein plays a role as a positive regulator of the WNT signaling pathway. It may be upregulated in tumor progression.[3]
References
References
- ↑ Yost C, Farr GH 3rd, Pierce SB, Ferkey DM, Chen MM, Kimelman D (Jul 1998). “GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis”. Cell. 93 (6): 1031–41. doi:10.1016/S0092-8674(00)81208-8. PMID 9635432.
- ↑ Saitoh T, Moriwaki J, Koike J, Takagi A, Miwa T, Shiokawa K, Katoh M (Mar 2001). “Molecular cloning and characterization of FRAT2, encoding a positive regulator of the WNT signaling pathway”. Biochem Biophys Res Commun. 281 (3): 815–20. doi:10.1006/bbrc.2001.4421. PMID 11237732.
- ↑ 3.0 3.1 “Entrez Gene: FRAT2 frequently rearranged in advanced T-cell lymphomas 2”.
Further reading
Further reading
- Bonaldo MF, Lennon G, Soares MB (1997). “Normalization and subtraction: two approaches to facilitate gene discovery”. Genome Res. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID 8889548.
- Bax B, Carter PS, Lewis C, et al. (2002). “The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation”. Structure. 9 (12): 1143–52. doi:10.1016/S0969-2126(01)00679-7. PMID 11738041.
- Freemantle SJ, Portland HB, Ewings K, et al. (2002). “Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2”. Gene. 291 (1–2): 17–27. doi:10.1016/S0378-1119(02)00594-2. PMID 12095675.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Deloukas P, Earthrowl ME, Grafham DV, et al. (2004). “The DNA sequence and comparative analysis of human chromosome 10”. Nature. 429 (6990): 375–81. doi:10.1038/nature02462. PMID 15164054.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). “The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)”. Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Stoothoff WH, Cho JH, McDonald RP, Johnson GV (2005). “FRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylation”. J. Biol. Chem. 280 (1): 270–6. doi:10.1074/jbc.M410061200. PMID 15522877.